Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (OCS) announced notifications of transactions by persons discharging managerial responsibilities related to the vesting and settlement of RSUs previously granted to company directors.

Named directors with RSU vesting notifications include Riad Sherif (6 March 2026), Robert Warner (4 March 2026), Arshad Khanani (4 and 6 March 2026), Christina Ackermann (4 March 2026) and Anthony Rosenberg (4 March 2026).

Key Figures

Publication date: 6 March 2026 RSU vesting date: 4 March 2026 Additional vesting date: 6 March 2026

3 metrics

Publication date 6 March 2026 Date of RSU transaction notification press release

RSU vesting date 4 March 2026 RSU vesting and settlement for several directors

Additional vesting date 6 March 2026 RSU vesting notification for Riad Sherif and Arshad Khanani

Market Reality Check

Price: $26.96 Vol: Volume 417,201 vs 20-day ...

normal vol

$26.96 Last Close

Volume Volume 417,201 vs 20-day avg 330,849 (relative volume 1.26) ahead of this routine disclosure. normal

Technical Price $27.74, trading above 200-day MA at $20.61 and about 9.58% below 52-week high.

Peers on Argus

OCS was little changed at +0.07% while biotech peers showed mixed moves: QURE up...

1 Down

OCS was little changed at +0.07% while biotech peers showed mixed moves: QURE up 17.81%, EYPT down 12.35%, others modestly up or down. Peer momentum data flags only AVXL moving down slightly, supporting a stock-specific, administrative nature for this RSU notice.

Historical Context

5 past events · Latest: Mar 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Annual report filing	Neutral	+0.1%	Filed 2025 audited IFRS financial statements and Form 20-F with attachments.
Mar 05	Conference participation	Positive	+0.1%	Announced March 2026 investor conferences with late-stage pipeline updates.
Mar 04	RSU vesting notice	Neutral	+0.1%	Disclosed RSU vesting and settlement for director Arshad Khanani.
Mar 03	Earnings and update	Positive	+0.5%	Reported 2025 results, strong cash position, and key Phase 3 milestones.
Feb 27	RSU vesting notice	Neutral	-2.7%	Notified market of RSU vesting and settlement for a director.

Pattern Detected

Positive fundamental updates (earnings, conferences) have recently seen modest positive price reactions, while prior RSU-related disclosures had limited and mixed impact.

Recent Company History

Over the past weeks, Oculis issued several updates, including Q4 and full-year 2025 results on Mar 3, 2026 highlighting cash of CHF 213.0M and progress across late-stage programs, followed by publication of 2025 IFRS financial statements on Mar 5, 2026. The company also announced participation in investor conferences and multiple notifications of RSU vesting for directors. These recent items collectively frame today’s RSU-related disclosure as part of an ongoing cadence of governance and reporting updates.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59

Shelf Active

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F-3 dated Nov 10, 2025 registers resale of up to 494,259 ordinary shares underlying a warrant. Oculis is not selling shares in this prospectus and would only receive up to $6,877,246.59 in cash if the warrant is fully exercised. The shelf is currently noted as not effective, with 0 recorded usages.

Market Pulse Summary

This announcement details the vesting and settlement of RSUs previously granted to several company d...

Analysis

This announcement details the vesting and settlement of RSUs previously granted to several company directors, a recurring governance disclosure for Oculis. It follows recent updates on 2025 financial statements, earnings, and clinical progress, all while the share price trades above its 200-day MA and near its 52-week high. Investors monitoring this name may focus more on upcoming late-stage ophthalmology milestones and the Form F-3 warrant structure than on routine RSU administration.

Key Terms

rsus

1 terms

rsus financial

"relate to the vesting and settlement of RSUs previously granted to directors"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. Not financial advice.

ZUG, Switzerland, March 06, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments

• Notification of managers' transaction - Riad Sherif - 6 March 2026 RSU vest
• Notification of managers' transaction - Robert Warner - 4 March 2026 RSU vest
• Notification of managers' transaction - Arshad Khanani - 4 March 2026 RSU vest
• Notification of managers' transaction - Christina Ackermann - 4 March 2026 RSU vest
• Notification of managers' transaction - Anthony Rosenberg - 4 March 2026 RSU vest
• Notification of managers' transaction - Arshad Khanani - 6 March 2026 RSU vest

FAQ

What did Oculis (OCS) announce about RSU vesting on March 6, 2026?

Oculis announced notifications of RSU vesting and settlement for several directors on March 4–6, 2026. According to Oculis, these filings record the completion of previously granted restricted stock units to named directors and show the dates of vesting and settlement.

Which Oculis directors had RSUs vesting in early March 2026?

Directors listed include Riad Sherif, Robert Warner, Arshad Khanani, Christina Ackermann, and Anthony Rosenberg. According to Oculis, the notifications cover vesting events dated 4 March 2026 and 6 March 2026 for those directors.

Does the Oculis RSU vesting announcement indicate any share issuance or dilution for OCS shareholders?

The announcement details RSU vesting and settlement but does not quantify shares or dilution. According to Oculis, the notifications report managers' transactions; no specific share counts or dilution metrics were provided in the notice.

Where can investors find the Oculis notifications of managers' transactions for OCS?

Investors can consult the company's regulatory notifications or filings that record managers' transactions. According to Oculis, the attached notifications accompany the announcement and identify each director and the RSU vesting dates.

What is the likely investor impact of the Oculis RSU vesting notifications for OCS?

The notice signals routine settlement of previously granted RSUs to directors rather than new compensation plans. According to Oculis, these are notifications of completed vesting events and do not include new guidance or financial metrics.